Summit Therapeutics Inc.

Equities

SMMT

US86627T1088

Market Closed - Nasdaq Other stock markets 21:00:00 17/04/2026 BST			5-day change	1st Jan Change
25.15 ^USD	+2.99%		+27.86%	+43.80%

03-27	Summit Therapeutics Inc. Announces Multiple Ivonescimab Data Sets from Phase III Studies in Advanced Nsclc Patient Populations to Be Featured At ELCC 2026	CI
03-11	Summit Therapeutics Inc. Presents at The Citizens Life Sciences Conference 2026, Mar-11-2026 02:15 PM

Transcript : Summit Therapeutics Inc. Presents at Citi Annual Global Healthcare Conference 2025, Dec-02-2025 10

Published on 12/02/2025 at 04:50 pm GMT - Modified on 12/02/2025 at 10:05 pm GMT

S&P Capital IQ

Presenter Speech
Yigal Nochomovitz (Analysts)

So welcome to the session of Citi's Global Healthcare Conference. Yigal Nochomovitz, biotech analyst. I've been covering Summit for a number of years now

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Summit Therapeutics Inc.

03-27	Summit Therapeutics Inc. Announces Multiple Ivonescimab Data Sets from Phase III Studies in Advanced Nsclc Patient Populations to Be Featured At ELCC 2026	CI
03-11	Summit Therapeutics Inc. Presents at The Citizens Life Sciences Conference 2026, Mar-11-2026 02:15 PM
03-02	Summit Therapeutics Inc. Presents at TD Cowen 46th Annual Health Care Conference, Mar-02-2026 02:30 PM
02-23	Summit Therapeutics Inc., Q4 2025 Earnings Call, Feb 23, 2026
02-23	Summit Therapeutics Q4 Net Loss Widens, Yearly Cash Equivalents Rise	MT
02-23	Earnings Flash (SMMT) Summit Therapeutics Inc. Posts Q4 Adjusted Loss $0.14 per Share, vs. FactSet Est of $-0.09	MT
02-23	Summit Therapeutics Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
02-09	Avacta appoints new chief scientific officer, plans clinical trials	AN
02-09	Avacta Therapeutics Announces Executive Changes	CI
01-29	Summit Therapeutics Announces U.S. FDA Acceptance of Biologics License Application Seeking Approval for Ivonescimab in Combination with Chemotherapy in Treatment of Patients with EGFRm NSCLC Post-TKI Therapy	CI
01-29	Summit Therapeutics Says US FDA Accepts BLA for Ivonescimab	MT
01-13	AbbVie Enters Cancer Treatment Space via RemeGen Licensing Deal, UBS Says	MT
01-12	Summit Therapeutics Inc. Announces Submission of Biologics License Application to U.S. FDA Seeking Approval for Ivonescimab in Combination with Chemotherapy in 2L+ Treatment of Patients with EGFRm NSCLC	CI
01-12	Summit Therapeutics Inc. Presents at 44th Annual J.P. Morgan Healthcare Conference, Jan-12-2026 09:45 AM
01-12	Summit Therapeutics, GSK Team up on Clinical Trial for Combination Cancer Therapy	MT